cox 189 has been researched along with Dysmenorrhea in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bitner, M; Gao, J; Hatfield, C; Kattenhorn, J; Kellstein, D | 1 |
| Bannwarth, B; Berenbaum, F | 1 |
| Barton, S; Daniels, S; Gitton, X; Stricker, K; Zhou, W | 1 |
1 review(s) available for cox 189 and Dysmenorrhea
| Article | Year |
|---|---|
Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2 Inhibitors; Diclofenac; Dysmenorrhea; Female; Gastrointestinal Hemorrhage; Humans; Osteoarthritis; Pain, Postoperative; Randomized Controlled Trials as Topic | 2005 |
2 trial(s) available for cox 189 and Dysmenorrhea
| Article | Year |
|---|---|
Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Dysmenorrhea; Female; Humans; Isoenzymes; Lactones; Membrane Proteins; Middle Aged; Organic Chemicals; Prostaglandin-Endoperoxide Synthases; Sulfones; Treatment Outcome | 2004 |
Efficacy and tolerability of lumiracoxib 200 mg once daily for treatment of primary dysmenorrhea: results from two randomized controlled trials.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dysmenorrhea; Female; Humans; Middle Aged; Naproxen; Pain Measurement; Treatment Outcome | 2008 |